Delivering affordable cancer care in high-income countries.

The burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not including direct medical costs) was estimated to be US$895 billion. This is not simply due to an inc...

Full description

Bibliographic Details
Main Authors: Sullivan, R, Peppercorn, J, Sikora, K, Zalcberg, J, Meropol, N, Amir, E, Khayat, D, Boyle, P, Autier, P, Tannock, I, Fojo, T, Siderov, J, Williamson, S, Camporesi, S, McVie, J, Purushotham, A, Naredi, P, Eggermont, A, Brennan, M, Steinberg, M, De Ridder, M, McCloskey, SA, Verellen, D, Roberts, T, Storme, G
Format: Journal article
Language:English
Published: 2011
_version_ 1797095042282684416
author Sullivan, R
Peppercorn, J
Sikora, K
Zalcberg, J
Meropol, N
Amir, E
Khayat, D
Boyle, P
Autier, P
Tannock, I
Fojo, T
Siderov, J
Williamson, S
Camporesi, S
McVie, J
Purushotham, A
Naredi, P
Eggermont, A
Brennan, M
Steinberg, M
De Ridder, M
McCloskey, SA
Verellen, D
Roberts, T
Storme, G
author_facet Sullivan, R
Peppercorn, J
Sikora, K
Zalcberg, J
Meropol, N
Amir, E
Khayat, D
Boyle, P
Autier, P
Tannock, I
Fojo, T
Siderov, J
Williamson, S
Camporesi, S
McVie, J
Purushotham, A
Naredi, P
Eggermont, A
Brennan, M
Steinberg, M
De Ridder, M
McCloskey, SA
Verellen, D
Roberts, T
Storme, G
author_sort Sullivan, R
collection OXFORD
description The burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not including direct medical costs) was estimated to be US$895 billion. This is not simply due to an increase in absolute numbers, but also the rate of increase of expenditure on cancer. What are the drivers and solutions to the so-called cancer-cost curve in developed countries? How are we going to afford to deliver high quality and equitable care? Here, expert opinion from health-care professionals, policy makers, and cancer survivors has been gathered to address the barriers and solutions to delivering affordable cancer care. Although many of the drivers and themes are specific to a particular field-eg, the huge development costs for cancer medicines-there is strong concordance running through each contribution. Several drivers of cost, such as over-use, rapid expansion, and shortening life cycles of cancer technologies (such as medicines and imaging modalities), and the lack of suitable clinical research and integrated health economic studies, have converged with more defensive medical practice, a less informed regulatory system, a lack of evidence-based sociopolitical debate, and a declining degree of fairness for all patients with cancer. Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system. A radical shift in cancer policy is also required. Political toleration of unfairness in access to affordable cancer treatment is unacceptable. The cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices and real value from new technologies.
first_indexed 2024-03-07T04:22:22Z
format Journal article
id oxford-uuid:cb748820-c47c-4d05-82ac-ad85a844be58
institution University of Oxford
language English
last_indexed 2024-03-07T04:22:22Z
publishDate 2011
record_format dspace
spelling oxford-uuid:cb748820-c47c-4d05-82ac-ad85a844be582022-03-27T07:15:00ZDelivering affordable cancer care in high-income countries.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cb748820-c47c-4d05-82ac-ad85a844be58EnglishSymplectic Elements at Oxford2011Sullivan, RPeppercorn, JSikora, KZalcberg, JMeropol, NAmir, EKhayat, DBoyle, PAutier, PTannock, IFojo, TSiderov, JWilliamson, SCamporesi, SMcVie, JPurushotham, ANaredi, PEggermont, ABrennan, MSteinberg, MDe Ridder, MMcCloskey, SAVerellen, DRoberts, TStorme, GThe burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not including direct medical costs) was estimated to be US$895 billion. This is not simply due to an increase in absolute numbers, but also the rate of increase of expenditure on cancer. What are the drivers and solutions to the so-called cancer-cost curve in developed countries? How are we going to afford to deliver high quality and equitable care? Here, expert opinion from health-care professionals, policy makers, and cancer survivors has been gathered to address the barriers and solutions to delivering affordable cancer care. Although many of the drivers and themes are specific to a particular field-eg, the huge development costs for cancer medicines-there is strong concordance running through each contribution. Several drivers of cost, such as over-use, rapid expansion, and shortening life cycles of cancer technologies (such as medicines and imaging modalities), and the lack of suitable clinical research and integrated health economic studies, have converged with more defensive medical practice, a less informed regulatory system, a lack of evidence-based sociopolitical debate, and a declining degree of fairness for all patients with cancer. Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system. A radical shift in cancer policy is also required. Political toleration of unfairness in access to affordable cancer treatment is unacceptable. The cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices and real value from new technologies.
spellingShingle Sullivan, R
Peppercorn, J
Sikora, K
Zalcberg, J
Meropol, N
Amir, E
Khayat, D
Boyle, P
Autier, P
Tannock, I
Fojo, T
Siderov, J
Williamson, S
Camporesi, S
McVie, J
Purushotham, A
Naredi, P
Eggermont, A
Brennan, M
Steinberg, M
De Ridder, M
McCloskey, SA
Verellen, D
Roberts, T
Storme, G
Delivering affordable cancer care in high-income countries.
title Delivering affordable cancer care in high-income countries.
title_full Delivering affordable cancer care in high-income countries.
title_fullStr Delivering affordable cancer care in high-income countries.
title_full_unstemmed Delivering affordable cancer care in high-income countries.
title_short Delivering affordable cancer care in high-income countries.
title_sort delivering affordable cancer care in high income countries
work_keys_str_mv AT sullivanr deliveringaffordablecancercareinhighincomecountries
AT peppercornj deliveringaffordablecancercareinhighincomecountries
AT sikorak deliveringaffordablecancercareinhighincomecountries
AT zalcbergj deliveringaffordablecancercareinhighincomecountries
AT meropoln deliveringaffordablecancercareinhighincomecountries
AT amire deliveringaffordablecancercareinhighincomecountries
AT khayatd deliveringaffordablecancercareinhighincomecountries
AT boylep deliveringaffordablecancercareinhighincomecountries
AT autierp deliveringaffordablecancercareinhighincomecountries
AT tannocki deliveringaffordablecancercareinhighincomecountries
AT fojot deliveringaffordablecancercareinhighincomecountries
AT siderovj deliveringaffordablecancercareinhighincomecountries
AT williamsons deliveringaffordablecancercareinhighincomecountries
AT camporesis deliveringaffordablecancercareinhighincomecountries
AT mcviej deliveringaffordablecancercareinhighincomecountries
AT purushothama deliveringaffordablecancercareinhighincomecountries
AT naredip deliveringaffordablecancercareinhighincomecountries
AT eggermonta deliveringaffordablecancercareinhighincomecountries
AT brennanm deliveringaffordablecancercareinhighincomecountries
AT steinbergm deliveringaffordablecancercareinhighincomecountries
AT deridderm deliveringaffordablecancercareinhighincomecountries
AT mccloskeysa deliveringaffordablecancercareinhighincomecountries
AT verellend deliveringaffordablecancercareinhighincomecountries
AT robertst deliveringaffordablecancercareinhighincomecountries
AT stormeg deliveringaffordablecancercareinhighincomecountries